Alpha-Mannosidosis (Mannosidosis, Alpha Type)
A rare inherited disorder caused by deficiency of the enzyme alpha-mannosidase, leading to progressive skeletal, immune, hearing, and neurological involvement of varying severity.
- MAN2B1 Genetic Testing
- Enzyme Replacement Access
- Multidisciplinary Specialist Review
- Most Common Onset
- Early Childhood
- Inheritance
- Autosomal Recessive (MAN2B1 Gene)
- Estimated Incidence
- ~1 in 500,000 Births
- Advanced Therapies
- Enzyme Replacement Therapy (Velmanase Alfa)
Condition Overview
Alpha-mannosidosis is a rare inherited lysosomal storage disorder caused by deficiency of the enzyme alpha-mannosidase, encoded by the MAN2B1 gene. Without sufficient enzyme activity, partially degraded sugar chains (oligosaccharides) accumulate in cells throughout the body, affecting the skeleton, immune system, hearing, and in many cases the nervous system.
The condition spans a wide severity spectrum, from a milder form recognized in later childhood or adulthood to a severe form presenting in early childhood with significant developmental and neurological involvement.
Because symptoms develop gradually and overlap with other connective tissue and immune conditions, alpha-mannosidosis is sometimes diagnosed after a prolonged evaluation. Early recognition allows for monitoring and, where appropriate, enzyme replacement therapy.
Types and Subtypes
Alpha-mannosidosis is broadly classified by severity and age of onset, though presentation exists along a continuum.
Symptoms and Signs
Symptoms develop gradually and reflect the multisystem nature of the disorder.
Causes and Risk Factors
Alpha-mannosidosis is a genetic condition and is not caused by lifestyle or environmental factors.
Diagnosis and Investigations
Diagnosis relies on enzyme testing, genetic confirmation, and imaging to characterize the extent of organ involvement.
Disease Severity and Risk Stratification
Alpha-mannosidosis is not formally staged, but clinicians classify disease by severity tier to guide monitoring and treatment intensity.
Standard Treatment Options
Management combines enzyme replacement therapy where available with proactive monitoring and treatment of organ-specific complications.
Advanced and Emerging Treatment Options
Enzyme replacement therapy represents the main disease-modifying option currently available; research into additional approaches continues.
Enzyme Replacement Therapy
Velmanase Alfa
A recombinant human alpha-mannosidase enzyme replacement approved in several regions for non-neurological manifestations of alpha-mannosidosis.
Cellular Therapy
Hematopoietic Stem Cell Transplant
Has been used in some severe early-onset cases to address broader systemic and some neurological manifestations, with outcomes varying by timing and disease severity.
Gene Therapy
Investigational Gene Therapy Approaches
Early research is exploring gene-based strategies aimed at addressing neurological manifestations not reached by current enzyme replacement therapy.
Biomarkers and Precision Medicine
Biochemical markers support diagnosis and help monitor response to treatment over time.
When a Second Opinion May Be Important
A second opinion can be helpful at several points given the broad severity spectrum of alpha-mannosidosis.
Clinical Trials and Research
Prognosis and Key Outcome Factors
Outcomes in alpha-mannosidosis depend on disease type, the degree of organ involvement at diagnosis, and access to ongoing specialist management.
Supportive Care and Living With Alpha-Mannosidosis
A multidisciplinary approach addressing hearing, skeletal, immune, and developmental needs is central to long-term care.
How CancerFax Helps You Explore Treatment Options
CancerFax helps families affected by alpha-mannosidosis with medical report review, second opinion coordination with metabolic disease specialists, and guidance on accessing enzyme replacement therapy and specialist centers.
Get a free case reviewFrequently Asked Questions
Alpha-mannosidosis is a rare inherited lysosomal storage disorder caused by deficiency of the enzyme alpha-mannosidase, leading to accumulation of oligosaccharides that affect the skeleton, immune system, hearing, and sometimes the nervous system.
Early signs often include recurrent infections, coarse facial features, hearing loss, and developmental or speech delay, typically noticed in early childhood.
Yes. It is inherited in an autosomal recessive pattern caused by mutations in the MAN2B1 gene.
Diagnosis involves measuring alpha-mannosidase enzyme activity, urine oligosaccharide testing, and confirmatory MAN2B1 genetic testing.
Enzyme replacement therapy with velmanase alfa is approved in several regions for non-neurological manifestations; supportive care addresses hearing, skeletal, and infection-related complications.
Yes. Type 1 is mild and later-onset, Type 2 is moderate, and Type 3 is severe with early childhood onset and significant neurological impact.
It can, particularly in the more severe disease types, though the degree of impact varies considerably between individuals.
It has been used in some severe early-onset cases; its role and timing are individualized decisions made with a specialist transplant team.
Care typically involves genetics, metabolic medicine, audiology, orthopedics, and developmental specialists working together.
Yes. CancerFax can help review medical and genetic reports, coordinate second opinions with metabolic disease specialists, and explore access to enzyme replacement therapy and specialist centers, including cross-border coordination where relevant.
Living With Alpha-Mannosidosis?
CancerFax can help you connect with metabolic disease specialists and explore enzyme replacement therapy access.